Zheng Quan Zhi Xing·2025-07-24 16:33Group 1 - The core opinion of the document is that the legal opinion confirms the compliance of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. with relevant regulations regarding the differentiated equity distribution plan for 2024 [2][3][6] - The differentiated equity distribution is based on the company's decision to repurchase shares for employee incentive plans and is in accordance with the Shanghai Stock Exchange's guidelines [3][5] - The total cash dividend to be distributed is approximately RMB 671,546,423.36, with a per-share cash dividend of approximately RMB 0.32 [6][7] Group 2 - The repurchased shares, totaling 19,906,252 A shares, do not participate in the profit distribution, which aligns with the regulations set forth by the Shanghai Stock Exchange [5][6] - The calculation of the ex-rights and ex-dividend reference price indicates a minimal impact on the stock price, with the absolute value of the impact being less than 1% [7][8] - The legal opinion emphasizes that the repurchased shares will not affect the distribution of dividends and confirms the legality and accuracy of the distribution plan [2][4][6]